Good problems to have? Policy and societal implications of a disease-modifying therapy for presymptomatic late-onset Alzheimer’s disease

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2195-7819

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Good problems to have? Policy and societal implications of a disease-modifying therapy for presymptomatic late-onset Alzheimer’s disease ; volume:16 ; number:1 ; day:12 ; month:10 ; year:2020 ; pages:1-11 ; date:12.2020
Life sciences, society and policy ; 16, Heft 1 (12.10.2020), 1-11, 12.2020

Creator: Angrist, Misha
Yang, Anna
Kantor, Boris
Chiba-Falek, Ornit

Contributor: SpringerLink (Online service)

DOI: 10.1186/s40504-020-00106-2

URN: urn:nbn:de:101:1-2020111219325099294661

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:33 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Angrist, Misha
Yang, Anna
Kantor, Boris
Chiba-Falek, Ornit
SpringerLink (Online service)

Other Objects (12)

Disease-modifying treatments in Alzheimer’s disease

Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers

Alzheimer’s Disease (AD) Detect & Prevent : presymptomatic AD detection and prevention

Identifying genetic interactions associated with late-onset Alzheimer’s disease

Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer’s disease

Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease

Genetic data and cognitively defined late-onset Alzheimer’s disease subgroups

Early and late-onset Alzheimer’s disease: What are the differences?

The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

A retrotransposon storm marks clinical phenoconversion to late-onset Alzheimer’s disease

Disease-modifying treatments in Alzheimer’s disease

Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers

Alzheimer’s Disease (AD) Detect & Prevent : presymptomatic AD detection and prevention

Identifying genetic interactions associated with late-onset Alzheimer’s disease

Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer’s disease

Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease

Genetic data and cognitively defined late-onset Alzheimer’s disease subgroups

Early and late-onset Alzheimer’s disease: What are the differences?

The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

A retrotransposon storm marks clinical phenoconversion to late-onset Alzheimer’s disease

Disease-modifying treatments in Alzheimer’s disease

Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers

Alzheimer’s Disease (AD) Detect & Prevent : presymptomatic AD detection and prevention

Identifying genetic interactions associated with late-onset Alzheimer’s disease

Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer’s disease

Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease

Genetic data and cognitively defined late-onset Alzheimer’s disease subgroups

Early and late-onset Alzheimer’s disease: What are the differences?

The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

A retrotransposon storm marks clinical phenoconversion to late-onset Alzheimer’s disease

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Good problems to have? Policy and societal implications of a disease-modifying therapy for presymptomatic late-onset Alzheimer’s disease

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Disease-modifying treatments in Alzheimer’s disease

Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers

Alzheimer’s Disease (AD) Detect & Prevent : presymptomatic AD detection and prevention

Identifying genetic interactions associated with late-onset Alzheimer’s disease

Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer’s disease

Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease

Genetic data and cognitively defined late-onset Alzheimer’s disease subgroups

Early and late-onset Alzheimer’s disease: What are the differences?

The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

A retrotransposon storm marks clinical phenoconversion to late-onset Alzheimer’s disease

Disease-modifying treatments in Alzheimer’s disease

Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers

Alzheimer’s Disease (AD) Detect & Prevent : presymptomatic AD detection and prevention

Identifying genetic interactions associated with late-onset Alzheimer’s disease

Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer’s disease

Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease

Genetic data and cognitively defined late-onset Alzheimer’s disease subgroups

Early and late-onset Alzheimer’s disease: What are the differences?

The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

A retrotransposon storm marks clinical phenoconversion to late-onset Alzheimer’s disease

Disease-modifying treatments in Alzheimer’s disease

Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers

Alzheimer’s Disease (AD) Detect & Prevent : presymptomatic AD detection and prevention

Identifying genetic interactions associated with late-onset Alzheimer’s disease

Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer’s disease

Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease

Genetic data and cognitively defined late-onset Alzheimer’s disease subgroups

Early and late-onset Alzheimer’s disease: What are the differences?

The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

A retrotransposon storm marks clinical phenoconversion to late-onset Alzheimer’s disease

Related objects

Reset password